New combination therapies to fight Carbapenem-resistant Pseudomonas aeruginosa in cancer patients
Official title: Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa
Funded at University of Colorado Denver · NIH-11580378 · Data updated 2026-11-12
Aims to create new drug combinations to treat a dangerous antibiotic-resistant lung/skin infections in cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | May 24, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $744,147 |
| NIH project number | 7R01AI165997-05 |
| Project ID | NIH-11580378 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with carbapenem-resistant, hypermutator Pseudomonas aeruginosa infections, including those associated with cancer.
✕Less likely to help
Patients without CRPA infections or without hypermutator strains may not benefit.
What this research studies
This project focuses on Pseudomonas aeruginosa strains that are resistant to carbapenems and carry hypermutator features. Researchers will explore non-natural nucleotides as part of combination therapies to overcome antimicrobial resistance and persistence. The work will look at how hypermutator bacteria adapt and how TLS Pol IV mutations contribute to treatment failure, with the goal of identifying effective regimens. The study uses prior anti-cancer nucleotide work to inform new antimicrobial strategies against MBL-producing strains. Results could lead to new treatment options for patients with CRPA infections in the cancer setting.
Why it matters
Potential benefit: If successful, patients with resistant Pseudomonas infections may have safer and more effective treatment options.
How similar studies have gone: Prior work shows promise for non-natural nucleotides as anti-cancer therapies; this project extends that approach to antimicrobial resistance, which is relatively novel.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Tsuji, Brian — University of Colorado Denver
- Study coordinator: Tsuji, Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.